JusticeItaly Official institution
Italy authorizes parallel import of the medicine Duspatal
Italy's medicines regulator AIFA has published a notice authorizing the parallel import of Duspatal, a human medicine. Parallel import means a medicine already approved in another country is brought into Italy and sold under a separate Italian permit. The notice is dated 3 November 2026 and carries the reference 26A05710. The excerpt does not give further terms of the authorization.
This summary was generated by AI; the official source prevails.
What does it mean?
Duspatal is already approved and sold in another country, and Italy has now allowed it to be brought in and sold there under a separate Italian permit. The notice is dated 3 November 2026.
Who is affected?
Patients who use Duspatal and the companies that would import and sell it in Italy.